131-radioiodine single dose in toxic diffuse goiter treatment calculated for goiter size and serum T3 levels

Enrique Hernández Salazar; Pedro Torres Ambriz; María Asunción Normandía Almeida; Ma. Eugenia Galindo Rujana; Norma Amador Licona; David González Bárcena

2003, Number 4

<< Back Next >>

Rev Endocrinol Nutr 2003; 11 (4)

131-radioiodine single dose in toxic diffuse goiter treatment calculated for goiter size and serum T3 levels

Hernández SE, Torres AP, Normandía AMA, Galindo RME, Amador LN, González BD

Full text

How to cite this article

Language: Spanish
References: 0
Page: 157-161
PDF size: 91.93 Kb.

ABSTRACT

Objective: To assess efficacy of a goiter size and serum T3 levels calculated radioiodine (I-131) single dose in toxic diffuse goiter treatment. Design: Quasy experimental study. Material and methods: From May 1, 1996 to May 31, 1997; 226 patients with toxic diffuse goiter diagnosis were treated with a I-131 single dose according to the following criteria: 10 mCi if they had a < 40 g goiter and < 400 ng/dL serum T3, n = 145 (64%); 20 mCi with a 40-60 g goiter and 400-600 ng/dL T3, n = 45 (19.9%) and 30 mCi with a > 60 g goiter and > 600 ng/dL T3, n = 36 (15.9%). Results: Efficacy of the single calculated I-131 dose was 99.1% in patients with toxic diffuse goiter. The Pearson’s “r” was 0.8803 with p < 0.0001 for goiter size and serum T3. Conclusions/B>: The I-131 dose, calculated by clinical means and serum T3 levels had a 99.1% efficacy.